#Sweden #Stockholm #Research Funding #EQT Foundation #brain medicine

EQT Foundation's Significant Contribution to Brain Medicine Research

On September 30, 2026, the EQT Foundation announced a substantial investment exceeding €1 million aimed at pioneering new methods to assist in delivering medicines across the blood-brain barrier. This innovative initiative supports 11 distinct research projects, each targeting the challenges faced when trying to effectively treat central nervous system (CNS) diseases.

The need to improve brain drug delivery methodologies arises from the complexity of the blood-brain barrier (BBB), a highly selective interface that acts as a protective shield for the brain. While it serves to keep harmful substances from affecting brain health, it also poses a significant obstacle for therapeutic agents. Many potentially effective treatments for neurological conditions are rendered useless due to their inability to penetrate this barrier.

Diverse Research Approaches

The funded projects are distributed across ten prominent research institutions spanning the Netherlands, Belgium, the United States, and Canada. Each project adopts a unique scientific approach, employing a variety of innovative techniques such as engineered biological carriers, molecular shuttles, and even cutting-edge AI technologies to navigate this critical barrier.

Some specific research initiatives include:

• - Extracellular Vesicles: Led by Elga de Vries from Amsterdam UMC, this project aims to develop naturally occurring particles that can transport therapeutic materials across the BBB.
• - GlycoShuttles: Sophia Shi of Harvard University is working on using glycans found on brain blood vessels to create a novel entry mechanism for therapeutics.
• - Gene Therapy Adapters: Researchers Maarten Dewilde and Els Henckaerts from KU Leuven are creating modulatory adaptors to enhance AAV gene therapy efficacy by targeting the BBB more effectively.
• - AI-Designed Shuttles: Umar Iqbal from Canada’s National Research Council is utilizing artificial intelligence to devise compact peptides designed to efficiently transport therapeutic agents into the brain.

These projects are not merely theoretical. Many are already applying their cutting-edge technologies to real-world medical conditions including brain cancer, amyotrophic lateral sclerosis (ALS), and rare genetic disorders, showcasing the promise of these innovative delivery strategies.

Groundbreaking Potential

Cilia Holmes Indahl, the Head of the EQT Foundation, expressed optimism regarding the transformative potential of these projects. She stated, “Science is increasingly designing sophisticated medicines, but the challenge lies in their delivery. This initiative explores a wide array of solutions, potentially benefiting multiple diseases simultaneously.” The overarching goal of the EQT Foundation’s commitment is to facilitate groundbreaking research that can lead to effective treatments for diseases that currently lack viable therapeutic options.

In total, the funding is not just a monetary investment; it also provides researchers access to invaluable expertise in commercialization and networks of industry professionals that can help transition their innovations from the lab to the market.

Conclusion

The EQT Foundation has positioned itself at the forefront of tackling the challenges presented by the blood-brain barrier, and its financial backing of diverse research projects might just lead to the development of revolutionary drugs capable of treating a host of CNS-related conditions. As these projects progress, they hold the promise of advancing therapeutic possibilities and improving the quality of life for patients facing currently untreatable neurological diseases.